Qritive
Qritive is a Singapore-based startup developing medical ai to provide clinical decision support for interpretations of pathology whole slide image scans.
 | |
| Status | Active |
|---|---|
| Website | https://www.qritive.com/ |
| Vertical(s) | Medtech, Artificial intelligence, Digital Health |
| Latest Funding Round | Series A |
| Year founded | 2017 |
| Headquarters | Singapore |
| Technology Readiness Level | Deployment (TRL 7-8) |
Technology
Qritive offers a suite of AI-powered diagnostic modules designed to support pathologists across a broad range of clinical applications—from cancer diagnosis and metastasis detection on Hematoxylin and Eosin stained whole-slide images to biomarker analysis on immunohistochemistry whole-slide images. Their modules are able to analyse entire whole-slide images within seconds[1].
Qritive has developed a comprehensive image management system to streamline pathology workflows from slide viewing and case management to AI-supported diagnosis and structured reporting[2].
Traction
The startup's diagnostic solution to support detection and grading of prostate cancer was given Class C In Vitro Diagnostic (IVD) Approval from Singapore’s Health Sciences Authority in August 2025[3] and regulatory approval from Abu Dhabi's Department of Health in July 2025[4].
In August 2025, Qritive announced that their lymph node metastasis detection solution would be adopted by Dr Lal PathLabs, an Indian diagnostic provider[5].
In September 2024, the startup announced a collaboration with Roche, to integrate their solution into Roche's digital pathology platform[6].
Accolades
In July 2025, the startup was selected as an awardee at the Japan Smart Healthy Aging QuickFire Challenge, an initiative by Johnson & Johnson Innovation to support breakthrough healthcare solutions focused on increasing healthy life expectancy in Japan[7].
Funding
Qritive raised a $7.5 million Series A round led by MassMutual Ventures in January 2023[8].
| Funding History | |
|---|---|
| Investor | Round |
| MassMutual Ventures | Series A |
| Seeds Capital | Series A |
| Exfinity Venture Partners | Series A |
Note: This list is community-maintained and may be incomplete or contain inaccuracies.
References
- ↑ "Other AI Modules". Qritive. Retrieved 2025-12-26.
- ↑ "Pantheon ™". Qritive. Retrieved 2025-12-26.
- ↑ Qritive (2025-08-05). "QAi Prostate Grade Receives Class C IVD Approval from Singapore's Health Sciences Authority". Qritive. Retrieved 2025-12-26.
- ↑ Qritive (2025-07-28). "QAi Prostate Grade Receives Regulatory Approval from Abu Dhabi's Department of Health". Qritive. Retrieved 2025-12-26.
- ↑ Qritive (2025-08-20). "Dr Lal PathLabs Selects Qritive's AI-Powered Solution to Strengthen Cancer Diagnostics". Qritive. Retrieved 2025-12-26.
- ↑ Qritive (2024-09-11). "Qritive Joins Forces with Roche to Redefine Global Cancer Diagnostics with AI". Qritive. Retrieved 2025-12-26.
- ↑ Qritive (2025-06-30). "Qritive Recognized in Japan Smart Healthy Aging QuickFire Challenge". Qritive. Retrieved 2025-12-26.
- ↑ "Healthcare AI Firm Qritive Raises $7.5M to Expand into New Markets". AP News. 2023-01-09. Retrieved 2025-12-26.